Weekly GLP-1 Receptor Agonists in Obese Individuals Without Diabetes

Sponsor
Zagazig University
Study ID
NCT07834398
Phase
PHASE3
Status
Completed

Conditions

  • Non-diabetec Obesity
  • Obesity (Disorder)

Eligibility Criteria

Sex
ALL
Age
18 Years - 65 Years
Healthy Volunteers
Accepted

Interventions

  • Dulaglutide — DRUG
    weight control drug dulaglutide 1.5 mg subcutaneous injection GLP-1 receptor agonist
  • Semagludtide — DRUG
    Weight control drug semaglutide 2.4 mg subcutanous injection GLP-1 receptor agonist
  • Tirzepatide — DRUG
    Weight control drug tirzepatide 15 mg subcutanous injection GLP-1 receptor agonist

Study Details

This randomized controlled trial evaluates the efficacy of three weekly GLP-1 receptor agonists (dulaglutide, semaglutide, and tirzepatide) in non-diabetic obese adults. 150 participants with BMI \>30 will be randomized into three groups and followed for 6 months to assess changes in weight, BMI, lipid profile, and liver functions.

Key Dates

First listed
Sep 22, 2026
Start date
Nov 14, 2025
Status verified
Sep 2026
Primary completion
Apr 13, 2026
Completion
Apr 21, 2026

Study Design

Enrollment
150 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Active Comparator: Dulaglutide Group
    Includes 50 non-diabetic obese participants receiving dulaglutide 1.5 mg subcutaneous once weekly for 24 weeks
  • Active Comparator: Semaglutide Group
    Includes 50 non-diabetic obese participants receiving semaglutide 2.4 mg subcutaneous once weekly for 24 weeks
  • Active Comparator: Tirzepatide Group
    Includes 50 non-diabetic obese participants receiving Tirzepatide 15 mg subcutaneous once weekly for 24 weeks

Primary Outcome Measure

change in body weight at 3 and 6 months [ Time Frame: Baseline, Week 12 (3 months) and Week 24 (6 months) ]

Related coverage on Hipa.ai

Related Studies